Anthropic has launched Claude Science, a new AI research platform designed to accelerate scientific discovery, and simultaneously announced that it will begin running its own internal drug discovery programs targeting neglected diseases — marking the AI company’s most ambitious expansion beyond software to date.
What Happened
On June 30, 2026, at an event in San Francisco, Anthropic unveiled Claude Science: a research environment built on top of its existing Claude models and integrated with more than 60 scientific databases spanning genomics, proteomics, cheminformatics, and clinical trial literature. The platform is designed to support scientific research in the same way that Claude Code supports software engineering — giving researchers a powerful, tool-connected AI collaborator purpose-built for scientific workflows.
Alongside the product launch, Anthropic confirmed it is establishing internal drug discovery programs of its own. These programs will focus on early, preclinical-stage research for diseases the company describes as “neglected” — conditions where the underlying biology is often well understood but the economics of traditional drug development are unattractive to large pharmaceutical companies.
Why It Matters
Claude Science places Anthropic directly into a three-way AI drug discovery race that now includes Google DeepMind and OpenAI. But Anthropic’s strategy has a distinctive twist: by actually building its own drug pipelines, the company is creating a direct feedback loop between AI development and scientific application. Hands-on drug development experience is expected to inform better AI products, which in turn attract paying biopharma customers.
Early customers for the Claude Science platform include Novo Nordisk and the Allen Institute — two organisations with very different scientific mandates, signalling that the platform is designed for broad use across academia and industry alike.
The launch also arrives as Anthropic’s commercial ambitions are accelerating rapidly. The company received Samsung, SK Hynix, and Micron as strategic infrastructure investors in its $65 billion Series H round in May 2026, and is now in early talks with Samsung to build a custom AI chip — clearly moving to diversify its revenue base well beyond the direct Claude subscription model.
Background & Context
Drug discovery is one of the domains where AI advocates have long promised transformational impact but delivered inconsistently. Early AI-discovered drug candidates have reached clinical trials in recent years, but none has yet achieved full regulatory approval. Anthropic’s bet is that using frontier language models — rather than the narrow, task-specific models common in early biotech AI — could meaningfully accelerate the process of identifying and validating drug targets.
The company is offering up to $30,000 in usage credits for up to 50 external research projects through Claude Science. Applications close July 15, 2026, with recipients to be announced by July 31. Critics have noted that the program, while generous, represents a relatively modest investment for a field where individual clinical trials can cost hundreds of millions of dollars.
What Comes Next
Anthropic has not specified which neglected diseases its internal programs will initially target, nor offered a timeline for preclinical results. The biotech industry will be watching closely — not just to evaluate Claude Science as a tool, but to see whether an AI lab without traditional pharmaceutical expertise can genuinely compete in early-stage drug research. Whatever the scientific results, the commercial logic is clear: Anthropic is positioning Claude Science as the platform for an entire generation of AI-native researchers, in the same way developer tools have made Claude Code the default environment for an AI-native generation of software engineers.
The same week Claude Science launched, Anthropic also released Claude Sonnet 5 and restored Fable 5 globally, making it one of the company’s most consequential product weeks since its founding.
